Cantor Fitzgerald Comments on AVITA Medical FY2025 Earnings

AVITA Medical, Inc. (NASDAQ:RCEL) – Cantor Fitzgerald issued their FY2025 earnings per share estimates for AVITA Medical in a report released on Tuesday, January 21st. Cantor Fitzgerald analyst R. Osborn anticipates that the company will post earnings per share of ($1.14) for the year. Cantor Fitzgerald currently has a “Overweight” rating and a $21.00 target price on the stock. The consensus estimate for AVITA Medical’s current full-year earnings is ($2.35) per share.

AVITA Medical (NASDAQ:RCEL) last posted its quarterly earnings data on Thursday, November 7th. The company reported ($0.62) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.41) by ($0.21). The business had revenue of $19.55 million for the quarter, compared to analysts’ expectations of $19.65 million. AVITA Medical had a negative return on equity of 194.69% and a negative net margin of 95.47%. During the same quarter in the prior year, the firm earned ($0.34) earnings per share.

Other analysts also recently issued research reports about the company. Lake Street Capital cut their target price on AVITA Medical from $20.00 to $14.00 and set a “buy” rating on the stock in a research note on Wednesday, January 8th. Piper Sandler reaffirmed a “neutral” rating and set a $12.00 target price (up from $9.00) on shares of AVITA Medical in a report on Friday, November 8th. Finally, D. Boral Capital reissued a “buy” rating and set a $25.00 target price on shares of AVITA Medical in a research note on Wednesday, January 8th. Two analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $18.00.

AVITA Medical Price Performance

Shares of NASDAQ RCEL opened at $8.95 on Wednesday. The company has a current ratio of 3.73, a quick ratio of 3.37 and a debt-to-equity ratio of 3.48. AVITA Medical has a twelve month low of $7.51 and a twelve month high of $18.93. The business has a 50 day simple moving average of $11.87 and a 200-day simple moving average of $10.64. The company has a market capitalization of $234.67 million, a price-to-earnings ratio of -4.01 and a beta of 1.58.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in RCEL. FMR LLC increased its stake in shares of AVITA Medical by 126.9% during the 3rd quarter. FMR LLC now owns 4,248 shares of the company’s stock worth $46,000 after purchasing an additional 2,376 shares during the last quarter. Huntington National Bank acquired a new stake in shares of AVITA Medical in the third quarter worth $32,000. Rhumbline Advisers grew its position in shares of AVITA Medical by 13.9% in the second quarter. Rhumbline Advisers now owns 36,530 shares of the company’s stock valued at $289,000 after purchasing an additional 4,463 shares during the last quarter. Quest Partners LLC increased its position in AVITA Medical by 269.4% in the 3rd quarter. Quest Partners LLC now owns 7,520 shares of the company’s stock worth $81,000 after buying an additional 5,484 shares during the period. Finally, IHT Wealth Management LLC grew its position in AVITA Medical by 24.3% in the 3rd quarter. IHT Wealth Management LLC now owns 28,100 shares of the company’s stock worth $301,000 after purchasing an additional 5,500 shares during the last quarter. Institutional investors and hedge funds own 27.66% of the company’s stock.

AVITA Medical Company Profile

AVITA Medical, Inc, together with its subsidiaries, operates as a regenerative medicine company in the United States and internationally. The company's lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds, full-thickness skin defects, and repigmentation of stable depigmented vitiligo lesions.